Eli Lilly and Company (LLY) caught investors’ attention after the pharmaceutical company reported strong Phase 3 results for its experimental drug retatrutide to treat patients with type 2 diabetes.
In the TRANSCEND-T2D-1 trial, retatrutide met all key endpoints, showing better blood sugar control and weight loss than placebo after 40 weeks. A1C levels, a measure of blood sugar, dropped by up to 2%, while patients lost an average of up to 36.6 pounds (16.8%). Notably, weight loss continued throughout the treatment period without slowing down.
Retatrutide also showed improvements in key cardiovascular risk factors, including cholesterol and blood pressure. The most common side effects were mild to moderate gastrointestinal issues such as nausea and diarrhea.
“With triple agonist retatrutide, we set out to make a molecule that could help patients achieve substantial A1C reduction and weight loss. These results support the remarkable potential of this novel molecule for people living with type 2 diabetes, with up to 2% A1C improvement and nearly 17% weight loss in 40 weeks of treatment,” said Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health.
LLY stock was little changed in pre-market trading on Thursday.
Get updates to this developing story on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.